Evidence map›Paper›PMID 24893982›Full record

ArticleCurrent infectious disease reports2014

Update on fungal diagnostics.

Allen T Griffin, Kimberly E Hanson

Abstract read
PubMed Publisher
In one paragraph

Article in Current infectious disease reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Plasma Microbial Cell-free DNA Metagenomic Sequencing for Diagnosis of Invasive Fungal Diseases Among High-risk Outpatient and Inpatient Immunocompromised Hosts.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  2. Review
  3. Article
  4. Comparative Evaluation of the BD Phoenix Yeast ID Panel and Remel RapID Yeast Plus System for Yeast Identification.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2016
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Allen T GriffinDepartment of Pathology, University of Utah, Salt Lake City, UT, USA, allen.griffin@aruplab.com.
Kimberly E Hanson
University of Utah · USUniversity Pathologists · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive fungal disease (IFD) is becoming more prevalent in transplant and oncology patients as a result of the potent immunosuppressive therapies used to prevent allograft rejection and/or the use of cytotoxic chemotherapy to treat cancer. Mortality attributable to IFD remains high despite advances in antifungal therapies. There is a continued need for laboratory diagnostics to help improve clinical outcomes. In recent years, culture-based detection strategies and histopathology have been supplemented with molecular and proteomic techniques as well as antigen detection methods. Refinements in these assays are improving the diagnosis of IFD, with the greatest strides made within the molecular and proteomic arenas. This review highlights recent laboratory developments in the diagnosis of invasive candidiasis, cryptococcosis, opportunistic molds, and endemic fungal infections.

Identifiers

PMID24893982
OpenAlexW2069285341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.